Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-19 Vaccine - Université de Lille Accéder directement au contenu
Article Dans Une Revue Cutis -New York- Année : 2022

Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-19 Vaccine

Résumé

Herpes zoster (HZ) was suspected as a predictive cutaneous manifestation of COVID-19, with a debated prognostic significance. We report a series of 5 cases of HZ occurring after vaccination with a nucleoside-modified messenger RNA (mRNA) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech). These new cases do not prove causality between COVID-19 vaccination and HZ. The pathophysiologic mechanism remains elusive, but local vaccine-induced immunomodulation may be involved. The occurrence of HZ does not justify avoiding the second injection of vaccine due to the benefit of vaccination.

Dates et versions

hal-04474420 , version 1 (23-02-2024)

Identifiants

Citer

Frédéric Dezoteux, Edouard Massip, Pierre Marcant, Annie Sobaszek, Marie-Charlotte Chopin, et al.. Herpes Zoster Following a Nucleoside-Modified Messenger RNA COVID-19 Vaccine. Cutis -New York-, 2022, Cutis -New York, 109 (1), pp.E5-E7. ⟨10.12788/cutis.0423⟩. ⟨hal-04474420⟩

Collections

RIIP UNIV-LILLE
14 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More